Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort.
Af Björkesten CG, Ilus T, Hallinen T, Soini E, Eberl A, Hakala K, Heikura M, Jussila A, Koskela R, Koskinen I, Moilanen V, Nielsen C, Nieminen U, Nuutinen H, Heikkinen M, Suhonen UM, Tillonen J, Utriainen K, Vihriälä I, Wennerström C, Borsi A, Nissinen R, Koivunen MR, Sipponen T.
Af Björkesten CG, et al. Among authors: wennerstrom c.
Eur J Gastroenterol Hepatol. 2020 Dec;32(12):1507-1513. doi: 10.1097/MEG.0000000000001831.
Eur J Gastroenterol Hepatol. 2020.
PMID: 32868649
Free PMC article.